In this article
FOXO4-DRI is a man-made peptide studied in anti-aging and longevity research. It is for research use only and is not approved by the FDA.
FOXO4-DRI
What it is
FOXO4-DRI is a man-made peptide (a short chain of amino acids, which are the building blocks that make up proteins) designed to enter cells. It is built using mirror-image amino acids arranged in reverse order. That design is called D-retro-inverso, which is where the "DRI" in the name comes from.
It is a fairly long peptide made up of about 46 amino acids. It is based on a natural protein called the FOXO4 transcription factor, which is a protein that helps control which genes get switched on or off inside a cell. Because it uses mirror-image amino acids, it resists being broken down by proteases, the enzymes that normally chop up peptides.
Research context and categorization
FOXO4-DRI is grouped under the anti-aging and longevity research category. More specifically, it is called a senolytic candidate. A senolytic is a compound studied for its ability to affect senescent cells. Senescent cells are old, worn-out cells that have stopped dividing but do not die off the way healthy cells do. Think of them like retired workers who stay at the office but no longer do any useful work.
Proposed Mechanism of Action
In lab and animal studies, researchers focus on two proteins: FOXO4 and p53. These two proteins work together, and that teamwork is thought to help old, worn-out cells survive instead of dying off naturally. The natural process of a cell dying on purpose is called apoptosis (think of it as a cell's built-in self-destruct button). Researchers study whether FOXO4-DRI can break up that FOXO4-p53 partnership and prompt those old cells to clear away in cell cultures (cells grown in lab dishes) and in rodent models.
It is also studied in the context of age-related tissue changes, scarring conditions such as keloids (raised, overgrown scars), and certain cancer-cell models. These uses are investigational only, meaning they are still in the research stage.
Key point: FOXO4-DRI has not been tested in completed human clinical trials. The effects described in the research literature are not confirmed or approved outcomes in humans.
Status
- Regulatory status: Research only. FOXO4-DRI is not FDA-approved for any use. There is no approved application on the public record. It is supplied for laboratory and research use only.
- Sport status: Prohibited under the WADA Prohibited List. WADA stands for the World Anti-Doping Agency. Because no government health authority has approved this peptide for human use, it falls under the S0 Non-Approved Substances category, which is banned at all times, both in and out of competition.
Reconstitution notes (general)
FOXO4-DRI is supplied as a lyophilized (freeze-dried) powder that is dissolved in liquid before use in the laboratory.
Working out the concentration is simple math. Concentration equals the amount of peptide in milligrams divided by the volume of liquid added in milliliters. For example, a 10 mg vial dissolved in 3 mL of bacteriostatic water (a special sterile water used in labs) gives a concentration of about 3.33 mg/mL.
To figure out a target concentration without doing the math by hand, use the peptide calculator.
Dilution and handling notes (compound-specific)
For a 10 mg vial, the reported range is roughly 2 mL of bacteriostatic water (giving about 5 mg/mL) to 3 mL (giving about 3.33 mg/mL). Using more water makes the solution more dilute, which can make it easier to measure out smaller amounts accurately.
Reconstitution Steps
To dissolve the powder gently, researchers typically follow these steps:
- Aim the liquid slowly down the inside glass wall of the vial rather than squirting it directly onto the powder.
- Let the vial sit briefly.
- Gently swirl or roll the vial between the palms rather than shaking it.
A properly dissolved solution should look clear and colorless, like plain water.
Because this is a long peptide, it is sensitive to oxidation (damage from contact with oxygen) and to being frozen and thawed more than once. The practical approach is to dissolve only what will be used, avoid shaking the vial hard, and keep the material protected from light.
If the solution stays cloudy, shows particles, or will not clear up, that is a sign the material has degraded (broken down) or was handled too roughly.
Handling and storage
Store dissolved material refrigerated at 2 to 8 C and out of direct light.
Recommended laboratory handling practices include:
- Wipe the vial stopper with an alcohol swab before drawing from it.
- Label the vial with the mix date so you can track how old the solution is.
- Treat a refrigerated solution as usable for roughly a 4-week window.
- Discard the vial if the contents become cloudy, discolored, or develop floating particles.
- Keep lyophilized (unmixed) powder frozen until you are ready to prepare it.
Related reading
Tools and supplies
- peptide calculator
- Bacteriostatic Water 30 ml
- Gansulin Metal Reusable Pen
- 3 ml Glass Cartridges (10-pack)
- Complete Starter Kit
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
What does D-retro-inverso mean in FOXO4-DRI?
The peptide is built from mirror-image (D-configuration) amino acids arranged in reverse sequence, increasing resistance to protease degradation compared with natural L-amino-acid peptides.
How is FOXO4-DRI reconstituted for laboratory use?
Dissolve the lyophilized powder in bacteriostatic water. Divide mg of peptide by mL of solvent to get mg/mL. A 10 mg vial with 2-3 mL of bacteriostatic water yields roughly 3.33-5 mg/mL.
What is FOXO4-DRI's regulatory and sport status?
It is not FDA-approved for any use. Under the WADA Prohibited List it is classified as an S0 Non-Approved Substance, banned at all times both in and out of competition.
What the research community gets wrong about FOXO4-DRI
FOXO4-DRI comes up often in longevity discussions, and a few ideas get repeated at the bench that do not hold up. Here are some points to keep straight when you are handling the vial.
- The "DRI" design does not make it indestructible in the vial. The D-retro-inverso build helps the peptide resist proteases (the enzymes that chop up peptides in a biological assay). That is not the same as being stable on your bench. Once reconstituted, it is still a long peptide that is sensitive to oxidation and to repeat freeze-thaw cycles.
- Rodent and cell-culture results are not human results. The effects people cite come from cells grown in dishes and from mouse models (for example, Baar and colleagues, 2017). There are no completed human clinical trials, so those outcomes are not confirmed in people.
- "Kills zombie cells" is a shortcut, not the mechanism. In the studied models it works by disrupting the FOXO4 and p53 interaction, which pushes p53 out and can trigger apoptosis (a cell's built-in self-destruct) in senescent cells. Whether that selectivity shows up depends on the exact cell type and conditions in the experiment.
- It is a peptide, not a small-molecule senolytic. People sometimes lump it in with small molecules studied as senolytics. Those are different classes of compound with different handling and different literature, so notes about one do not transfer to the other.
- A label that says 10 mg is a stated mass, not a confirmed identity or purity. The number on the vial does not verify what is inside. Treat the certificate of analysis and lot number as the real record, and log them before you reconstitute.
From our bench: If you work with FOXO4-DRI, we would like your real appearance data over time. After reconstituting a vial in bacteriostatic water, record the starting concentration (mg/mL), the storage temperature, and then note the solution's clarity at set check-ins across the refrigerated window. Tell us on which day, if any, you first saw cloudiness or particles, and how many freeze-thaw cycles the material went through before that point. Send the actual observations you logged, not estimates, and we will add anonymized results to this page.
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
- Baar et al., Cell (2017) , Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (original FOXO4-DRI report)
- Bourgeois & Madl, FEBS Letters (2018) , Regulation of cellular senescence via the FOXO4-p53 axis (review)
- Hu et al., Frontiers in Bioengineering and Biotechnology (2026) , FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
